免疫抑制药物对移植受者慢性鼻窦炎及内镜鼻窦手术的影响
肾移植受者使用抗胸腺细胞球蛋白诱导者慢性鼻窦炎风险升高(OR=3.0,95%CI[1.3,6.9],P=.005);肝移植受者使用环孢素、霉酚酸酯和糖皮质激素方案者慢性鼻窦炎风险高于他克莫司方案(OR=6.0,95%CI[1.5,24.1],P=.027),环孢素组内镜鼻窦手术率也更高(4.2% vs 0.3%,P=.015)。结论提示他克莫司方案与慢性鼻窦炎发生率降低相关。
要点
- 肾移植受者使用ATG诱导者慢性鼻窦炎风险升高(OR=3.0,P=.005)。
- 肝移植受者环孢素+MMF+激素方案慢性鼻窦炎风险高于他克莫司方案(OR=6.0)。
- 环孢素组内镜鼻窦手术率4.2%,高于他克莫司组的0.3%(P=.015)。
核心结论
- 他克莫司为基础的免疫抑制方案与肾或肝移植受者慢性鼻窦炎发生率显著降低相关,免疫抑制药物选择可能是可干预的鼻窦疾病风险因素。
研究设计与样本
- 共纳入1459例移植受者(986例肾移植,473例肝移植),平均年龄55.1岁,男女比1.5:1。
主要发现
- 肾移植受者接受抗胸腺细胞球蛋白(ATG,Thymoglobulin®)诱导者慢性鼻窦炎风险高于未使用者(OR=3.0,95%CI[1.3,6.9],P=.005)。
- 肝移植受者使用环孢素、霉酚酸酯(MMF)和糖皮质激素方案者慢性鼻窦炎风险高于他克莫司为基础方案者(OR=6.0,95%CI[1.5,24.1],P=.027)。
- 环孢素使用与内镜鼻窦手术率升高相关(4.2% vs 0.3%,P=.015)。
关键数值与推荐
- 慢性鼻窦炎诊断基于耳鼻咽喉科专科医师分配的ICD-10编码。
临床怎么用
- 对肾或肝移植受者,尤其是使用ATG诱导或环孢素联合MMF及激素方案者,应关注慢性鼻窦炎症状并考虑耳鼻咽喉科评估。
- 在免疫抑制方案选择时,他克莫司为基础方案可能降低慢性鼻窦炎及内镜鼻窦手术风险。
局限性
- 回顾性研究设计可能存在选择偏倚和混杂因素。
- 诊断依赖ICD-10编码,可能存在编码不准确或漏诊。
- 随访时间有限,未报告长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the impact of immunosuppressive regimens on chronic rhinosinusitis (CRS) development in kidney and liver transplant recipients. STUDY DESIGN: Retrospective cohort study. SETTING: Multisite study across Mayo Clinic Enterprise locations in Arizona, Florida, Minnesota, and Wisconsin. METHODS: Patients who underwent kidney or liver transplantation between November 1, 2021, and November 1, 2022, were included. Patients with documented sinonasal complaints before transplantation were excluded. Diagnoses were based on ICD-10 codes assigned by board-certified otolaryngologists, with follow-up extending through November 2024. Demographic data, relevant comorbidities, CRS diagnoses, and immunosuppressive regimens were collected. RESULTS: In total, 1459 transplant recipients (986 kidney, 473 liver) with a mean age of 55.1 years and M:F ratio of 1.5:1 were included. Kidney recipients who received anti-thymocyte globulin (ATG, Thymoglobulin®) for immunosuppressive induction had a greater risk of CRS compared to those who did not (odds ratio [OR] = 3.0, 95% CI [1.3, 6.9], P = .005). Among liver recipients, patients on cyclosporine, mycophenolate mofetil (MMF), and corticosteroids had a greater risk of CRS compared to those on tacrolimus-based regimens (OR = 6.0, 95% CI [1.5, 24.1], P = .027). Cyclosporine use was also associated with an increased rate of endoscopic sinus surgery (ESS) compared to tacrolimus (4.2% vs 0.3%, P = .015). CONCLUSION: Tacrolimus-based regimens are associated with significantly decreased rates of CRS compared to cyclosporine, suggesting that immunosuppressive choice is a modifiable risk factor for sinonasal morbidity in this population.
引用
- Daniel H, Valencia-Sanchez BA, Wadei H, et al. Impact of Immunosuppressive Medications on Chronic Rhinosinusitis and Endoscopic Sinus Surgery in Transplant Recipients. Otolaryngol Head Neck Surg. 2026. PMID: 41774565. doi:10.1002/ohn.70185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。